Basil Elnazir
Overview
Explore the profile of Basil Elnazir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walsh R, Costello L, DiCosimo A, Doyle A, Kehoe L, Mulhall C, et al.
Pediatr Res
. 2024 Jun;
96(7):1560-1567.
PMID: 38902454
Aim: Systematically review the management of infants with severe bronchiolitis in a paediatric intensive care unit (PICU) setting with a focus on high-risk infants to identify gaps in evidence-based knowledge....
2.
Yavuz S, Elnazir B, Amin S, Sherif A, Saif S, Francis N
Cureus
. 2024 Mar;
16(2):e54627.
PMID: 38524055
Cystic fibrosis (CF) is a recessively inherited disease most commonly seen in Caucasians. The mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene are responsible for the condition, and...
3.
Mainz J, Lester K, Elnazir B, Williamson M, McKone E, Cox D, et al.
J Cyst Fibros
. 2023 Oct;
23(3):474-480.
PMID: 37806792
Background: RECOVER is a multicentre post-approval study of Elexacaftor/Tezacaftor/Ivacaftor (ETI) in pwCF in Ireland and the UK. The CFAbd-Score is the first validated CF-specific patient reported outcome measure (PROM) focusing...
4.
McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, et al.
Am J Respir Crit Care Med
. 2023 Sep;
208(9):917-929.
PMID: 37703083
Clinical trials have shown that use of elexacaftor/tezacaftor/ivacaftor (ETI) is associated with improvements in sweat chloride, pulmonary function, nutrition, and quality of life in people with cystic fibrosis (CF). Little...
5.
McNally P, Linnane B, Williamson M, Elnazir B, Short C, Saunders C, et al.
Respir Res
. 2023 Aug;
24(1):199.
PMID: 37568199
Background: Data from clinical trials of lumacaftor-ivacaftor (LUM-IVA) demonstrate improvements in lung clearance index (LCI) but not in FEV in children with Cystic Fibrosis (CF) aged 6-11 years and homozygous...
6.
Ring A, Schwerk N, Kiper N, Tana Aslan A, Aurora P, Ayats R, et al.
ERJ Open Res
. 2023 Apr;
9(2).
PMID: 37101741
Background: Paediatric diffuse alveolar haemorrhage (DAH) is a rare heterogeneous condition with limited knowledge on clinical presentation, treatment and outcome. Methods: A retrospective, descriptive multicentre follow-up study initiated from the...
7.
Francis N, Yavuz S, Elnazir B
Cureus
. 2023 Feb;
15(1):e33337.
PMID: 36741604
Cystic fibrosis (CF) is an autosomal recessive disease caused by different mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It is the most common inherited disorder in the...
8.
Brannick S, McDonald M, Greally P, Elnazir B, Ahmareen O
Clin Case Rep
. 2022 Aug;
10(8):e6255.
PMID: 36017116
Omalizumab is a monoclonal antibody which targets immunoglobulin E. It is approved as an add-on therapy for children with severe allergic asthma. Assessment of endotype and phenotype is necessary in...
9.
Trayer J, Byrne A, Elnazir B
Ir J Med Sci
. 2022 Jul;
192(3):1271-1276.
PMID: 35804261
Background: Allergen immunotherapy (AIT) is a safe, effective and disease-modifying treatment for allergic rhinitis. It is indicated for children with moderate to severe disease whose symptoms persist despite conventional therapy....
10.
Maguire B, Blake O, Boran G, Borovickova I, Abdelfadil S, Murray C, et al.
J Cyst Fibros
. 2021 Oct;
21(3):416-421.
PMID: 34620573
Background: The sweat test has been the "gold standard" diagnostic test for cystic fibrosis for more than 40 years. We hypothesized that there would be a change in the pattern...